These findings suggest that the dual inhibition of XPO1 and BCL2 effectively enhances apoptosis and disrupts mitochondrial integrity in myeloma cells, making this combination a promising therapeutic strategy for targeting myeloma. The gene discussed is BCL2; the disease is plasma cell myeloma.